Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
atypical antipsychotics
Pharma
FDA questions Rexulti efficacy in PTSD after failed phase 3
“Discordant” trial results have FDA reviewers worried, especially since the agency said it was unable to identify an explanation for the outcomes.
Angus Liu
Jul 16, 2025 2:38pm
BMS' schizophrenia drug stumbles in blow to blockbuster plan
Apr 23, 2025 10:35am
Intra-Cellular's unstoppable Caplyta nails another trial
Nov 5, 2024 10:15am
Intra-Cellular moves closer to Caplyta depression expansion
Apr 16, 2024 2:27pm
Rovi wins FDA nod to make Moderna's COVID shot at Spanish plant
Feb 28, 2024 11:22am
Teva taps Royalty to bankroll long-acting schizophrenia drug
Nov 13, 2023 11:40am